Jacqueline S. Armani, O.D., F.A.A.O., graduated from the New England College of Optometry, externed at Bascom Palmer and practiced at the VA as a primary care and ocular disease resident optometrist. Jackie has extensive experience training and mentoring residents and students and is a Fellow of the American Academy of Optometry. She joined industry following years of clinical practice as Executive Clinical Outcomes Specialist at Bausch and Lomb. Jackie is now a Medical Science Liaison at Alcon Surgical where she supports over 20 products in 6 product categories. Jackie’s career has included her medical mission in Colombia with VOSH and South Africa with OneSight Global. She resides in New York, volunteers on her alumni board, and loves to travel and plan events.
Gina Barbarotto is Director, Patient & Professional Relations, at Purdue Pharma L.P. Her primary role is developing the strategy, processes and alignment around thought leader management enterprise-wide. In addition, Gina is responsible for cultivating and maintaining relationships with healthcare professional associations and patient advocacy groups to optimize effective communication and engagement. Gina’s diverse experiences in pharmaceuticals and healthcare include diagnostics, scientific publishing and communications, global and US marketing, genetics research and medical technology.
Gina joined Purdue in 2009 and has held positions at Abbott Laboratories, Mayo Clinic and St. Francis Hospital in Escanaba, MI – all of which afforded her critically different perspectives on the healthcare arena and the experiences of clinicians, patients, and caregivers. She has an MBA with an International Specialization, an MS in Molecular Genetics and a BS in Medical Technology. She also enjoys teaching group exercise classes. Gina serves on the board of the Interstitial Cystitis Association.
Talia Biran has served as Executive Director, Medical Affairs, Oncology at Lexicon from 2013-2017. Talia is a Global Medical Affairs leader who brings more than 20 years of diverse experience in the pharmaceutical industry. She has worked for companies such as Novartis, Merck, and Janssen and has gained particular expertise in Oncology, infectious disease, and endocrinology. Talia brings an in-depth understanding of drug development across all stages of development, therapeutic area, scientific and market needs. Over her career, Talia has successfully contributed to the development, approval and launch of several drugs, including Abiraterone Acetate (Zytiga ®, prostate cancer), Vorinostat (Zolinza®, CTCL), Letrozole (Femara®, breast cancer), Octreotide (Sandostatin LAR®, neuroendocrine tumors (NETs) and acromegaly) and Telotristat Ehtyl (Xermelo®, Carcinoid Syndrome Diarrhea).
Immediately before joining Lexicon, Talia worked at Janssen R&D, Inc. where she directed clinical operation efforts for global Phase I-III R&D and Medical Affair programs of Abiraterone Acetate (ZYTIGA) in Metastatic Prostate Cancer. While there, she contributed to the drug’s successful worldwide NDA submission and FDA approval.
Prior to Janssen, Talia was a Medical Science Liaison for Merck Oncology where she served as the primary conduit for scientific and medical exchange with national investigators and key opinion leaders at academic institutions and cooperative groups. In that role, she provided guidance and expertise to the design of phase IIV clinical trials and LCM development. Additionally, she led the development of a strategic, global collaborative partnership between Merck Research Labs and 16 major global cancer centers with early development capabilities (MRL Oncology Network – OncoNet) to advance scientific collaborations of shared interest. Her work enhanced the execution of Phase II-III clinical trials for Merck’s oncology compounds in development across multiple tumor types.
Prior to Merck, Talia worked at Novartis Oncology GMA, where she interfaced with the marketing team, trained global Medical Liaisons and directed the development and implementation of scientific communication, publication strategies, and programs supporting pipeline and marketed products worth over $2 billion in sales. Talia holds a Master of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, in Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorigenesis.
Margaret A. Campbell, PharmD is a native of Carrollton Georgia and attended the University of West Georgia before receiving her Doctor of Pharmacy degree from Mercer University School of Pharmacy. She began her career at the Veterans Affairs Medical Center as the Clinical Pharmacy Coordinator with a focus on cardiovascular and critical care medicine. Her clinical practice continued as the Director of Clinical Research and Education with Southeastern Cardiology Consultants where she was responsible for Phase III-IV clinical trials as well as patient management for heart failure and cardiovascular risk reduction.
Dr. Campbell has conducted research and published abstracts and posters in the areas of hypertension, hyperlipidemia, diabetes, cardiovascular risk reduction, women’s health and outcomes research. Dr. Campbell has 18 years of pharmaceutical and medical device industry as a Medical Science Liaison as well as a National Director for a field base medical team. Currently, Dr. Campbell resides in Hattiesburg Mississippi and is the Cardiovascular Medical Science Liaison Director for Novartis Pharmaceuticals.
Often viewed as KOL himself by his peers on the industry side, Nelson has extensive experience in the area of KOL development and management. Nelson has led the effort to develop a scientific platform relevant to the brand’s clinical profile and positioning and to identify, profile, segment and engage KOLs to deliver on the organizational objectives for the brand. Working with KOLs based in the U.S. and in key international markets, Nelson has accrued a strong record of accomplishments by leveraging KOL expertise and driving for thorough plan implementation across the entire organization.
With more than 18 years of diversified experience in the life sciences vertical, Peter has been involved in digital pharmaceutical communications since 1996. His leadership in strategic planning, revenue generation, and business partnering has established a strong and diverse client base for Within3. His expertise and experience in working closely with organizations to adopt new technologies prove invaluable to clients and partners as they adopt new solutions. His consultative demeanor and willingness to work collaboratively continually provide benefits to clients and partners old and new as Within3’s business grows and evolves.
As part of the leadership team for Hyphen, an Omnicom-owned digital agency, Peter developed and implemented strategies that established Hyphen’s market presence, grew product offerings, and drove business development and customer acquisition. Hyphen grew exponentially from 2003 to 2007, quadrupling staff and revenues while acquiring new clients and opportunities annually. Peter has also held positions with Sermo, Peer Direct, Torre Lazur and Commonhealth developing business and leading accounts. Peter has worked extensively across the industry resulting in successful innovation for clients and healthcare professionals alike.
Robert B Geller, MD received a B.S. and M.S. in physics from M.I.T., an MD from Harvard Medical School, and then completed a medical residency at the Hospital of the University of Pennsylvania, and a fellowship in medical oncology at the Johns Hopkins Cancer Center. He has held academic positions at the University of Chicago and Emory University as Director, Stem Cell Transplantation Program, and the Leukemia Program, respectively, where he was involved with new treatment strategies, supportive care, and drug development for patients with blood cancers for those undergoing stem cell transplants. He has held positions at Vion Pharmaceuticals and Alexion, and is currently Vice President, Medical Affairs, Heron Therapeutics, where he has developed a medical affairs department to support the approval and launch of SUSTOL (granisetron) extended-release injection, and for CINVANTI (polysorbate-free IV aprepitant), and the early development of HTX-011 a polymer of bupivacaine and meloxicam being developed for post-surgical pain.
18-year background in the pharmaceutical and medical device sectors with expertise in healthcare medical affairs, sales execution, territory development, and product development. Fully experienced in startup environments, complex healthcare selling process, business development, team leadership, and contract negotiation.
Mary Michael is an innovative and trailblazing senior leader in the healthcare industry. She has an unparalleled track record of success in developing and incubating novel business solutions across a diverse portfolio of healthcare arenas, including biopharmaceuticals, orphan disease, digital health, and technology alliance partnerships. Mary is currently the Vice President of Patient Advocacy and Stakeholder Management at Otsuka America Pharmaceutical, Inc. In this role, Mary has championed a vast array of first-in-company and first-in-industry initiatives.
While at Otsuka, Mary spearheaded the launch of the Global Council on Alzheimer’s Disease (GCAD). GCAD is a collection of preeminent opinion leaders across the sectors that influence the Alzheimer’s space, including science, medicine, and policy, but also caregiving, technology, finance, religion, and law. In its first three years, GCAD created a set of online resources for caregivers; it crafted an Alzheimer’s Patient Navigation Model and published this concept in multiple peer-reviewed journals; and it launched a year-long initiative to spur innovation for Alzheimer’s within the technology community. Mary partnered with AGE-Well to develop and host a Pitch Event to Disrupt AD through Technology at the 2016 AAIC meeting. Mary’s leadership of GCAD pillar projects were showcased at the 2016 Alzheimer’s Europe Congress with both a poster and oral presentation within the scientific programme. Mary also joined the Dementia Action Alliance Scientific Advisory Board in 2016.
Before joining Otsuka, Mary spent nine years Wyeth Pharmaceuticals (Pfizer) in the area of Opinion Leader and Advocacy Relations, where she was accountable for the leadership, development, and execution of Global Opinion Leader (OL) business strategies and plans based upon clinical, medical and commercial business objectives. Prior to her work at Wyeth, Mary spent 13 years with Bristol-Myers Squibb, where she held a variety of positions.
Bob Numerof, PhD, is a medical affairs professional having worked in the medical affairs function at Bayer Healthcare, Baxter, and CSL Behring over the past 10+ years. His roles have included strategy development, medical communications, KOL management, Phase IV/post-marketing study design and implementation, and most recently, field team leadership. Prior to his work in medical affairs, Bob had a research career at the NIH and in the biotech/pharmaceutical industry focusing primarily on immunology and inflammation. He received a PhD in Immunology from Tufts University.
Tony has 30 years of experience creating and delivering strategic intelligence products and services. In his past career in the US intelligence community, he directed intelligence operations in various strategic analysis organizations in the US and abroad. Tony now leads Voxx Analytics, which brings rigorous analytics to bear on influence-related challenges.
Kevin is an attorney in the general legal department of Novo Nordisk with responsibility for providing comprehensive legal support to several therapeutic areas and all phases of pharma development from preclinical to marketed products. Kevin also provides legal support to the Novo Nordisk Government Affairs office. Prior to joining Novo Nordisk, Kevin was an associate at several large law firms and prior to law school worked as a discovery research scientist for Wyeth Pharmaceuticals.
David Lee Scher, M.D., is a practicing cardiac electrophysiologist and Director at DLS Healthcare Consulting, LLC, where he advises mobile health companies as well as their partners and investors. Scher was a pioneer adopter of remote patient monitoring and the integration of monitored devices and electronic health records. He is a recognized world expert in mobile health technologies, specifically remote patient monitoring and mobile medical apps. He is a well-known technology and patient advocate in the world of social media and his blog, The Digital Health Corner, is well-respected. Scher served as Chair of Happtique’s Blue Ribbon Panel which developed standards for certification of mobile medical apps. He is an active leader at mHIMSS, serving as member of the Advisory Council and Chair of its Roadmap Task Force. Scher’s experiences as a clinician, Medicare committee member and chair of a large Human Research Subject Committee give him a unique perspective as a consultant.
Jeff has 12 years of experience planning global projects for pharmaceutical companies, including four years in logistics and five years in strategy/program execution. He has extensive knowledge in KOL engagement strategy and sets best practices related to global/regional/affiliate communications for launch planning and global deliverable development. Jeff’s therapeutic experience includes neuroscience (psychiatric disorders and Alzheimer’s disease), cardiovascular, osteoporosis, and oncology. He also brings experience in curriculum design and adult learning principles, which have been utilized in corporate training programs for a major pharmaceutical company.
A graduate of Northern Arizona University with a Bachelor of Science in public relations, Jeff is a seasoned domestic and international traveler. His previous experience includes three-and-a-half years working as a senior project manager for an international meeting planning company, focusing on the pharmaceutical industry. Prior to that role, he managed the training curriculum design and education initiatives for an international membership organization for four years.
Jeff has been with Avant Healthcare since 2007 and is a certified Lean Six Sigma Yellow Belt. He is a board member with the Crisis Center of Johnson County and the advisory board chairman for the Iowa Chapter of Delta Upsilon Fraternity, and he serves as a trustee for the Iowa City Community Fund.
John Sears is currently a Director of Health Care Quality Strategy with Johnson & Johnson Health Care Systems. In his current role, John develops internal commercial strategies that support pipeline, inline and above-brand workstreams by bridging any gaps between Janssen’s capabilities and the evolving US healthcare system. John has previous experience with global marketing, sales operations, medical affairs and business consulting working across the majority of therapeutic areas within Janssen.
With several years of focused effort inside the pharmaceutical vertical, Badal Shah, B.Pharm, M.S. MBA, has pioneered a framework for achieving effective medical communications and optimizing field sales force activities pre- and post-launch for pharmaceutical products. With his revolutionary approach to Key Opinion Leader (KOL)/HCP engagement, Badal established and leads the KOL practice and serves as the Director, Health Analytics at QPharma. His ability to create cohesive tools for interlocking compliance and commercial solutions within the KOL Healthcare Practitioner (HCP) space has been well-received and lauded by current and prospective pharmaceutical clients of QPharma. A Pharmacist and business graduate of Rutgers University, Shah is a member of the Advisory Board of Directors for the American Pharmacy Purchasing Alliance.
Sherrie Smartt, RN, MSN, MHA functions in the role of Medical Director, Clinical Studies & Regulatory Affairs Manager for Thermo Fisher Diagnostic Biomarkers– North America.
As a member of the global Biomarkers Medical Affairs team, she is responsible for providing scientific, clinical and regulatory strategic direction to support introduction of high-value, novel biomarkers to the health care environment in the US and Canada. Priorities include building relationships with clinicians and researchers to uncover medical value gaps to inform the North American clinical study strategy. Her reporting team includes a Medical Affairs manager focused on execution of clinical studies and a Clinical Operations Manager leading 10 Medical Science Liaisons (MSLs) specialized in comprehensive knowledge and clinical expertise of proCalcitonin in infectious disease and sepsis.
Sherrie previously functioned as the Lead Medical Scientific Liaison for US Roche Diagnostics Medical & Scientific Affairs Division out of Indianapolis, IN – specializing in cardiac biomarkers.
Sherrie leverages 20 years in Critical Care clinical practice with extensive experience across the spectrum of critical care, perianesthesia, and cardiovascular healthcare.
Dr. Vlajnic currently holds the position of Vice President, US Medical Affairs, General Medicine within Bayer Pharmaceuticals, where she is responsible for leading a team of Medical Directors and Field Medical Liaisons working on rare diseases in cardio-pulmonary, cardio-renal, infectious diseases, hematology, and prescription dermatology.
Prior to joining Bayer, Dr. Vlajnic served as a Global Medical Affairs Head, LixiLan Franchise within the Sanofi diabetes portfolio. She also served in various US and Global leadership positions, building and leading international and cross-functional teams. Aleksandra started her career at Aventis Pharmaceuticals as a Medical Director in the Endocrinology, and later moved to positions with increasing management responsibilities within Aventis and later Sanofi.
Dr. Vlajnic holds a Nursing and a Medical Doctor Degree from the University Of Novi Sad, Serbia, and a MBA Degree from the University of Phoenix, Arizona. She authored numerous publications in the area of metabolism and pharmaceutical medicine.